Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Bou Samra, Elias ^a   Klein, Bernard ^a,b   Commes, Thérèse ^a,b   Moreaux, Jérôme ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PRECURSOR PROTEIN BINDING FAMILY A MEMBER 2; AMYLOID PRECURSOR PROTEIN; C TYPE LECTIN DOMAIN FAMILY 4 MEMBER A; CHROMOSOME 10 OPEN READING FRAME 10 PROTEIN; DECTIN 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FAMILY WITH SEQUENCE SIMILARITY 101 MEMBER B PROTEIN; FOLLICULIN INTERACTING PROTEIN 2; LECTIN; LYMPHOCYTE CYTOSOLIC PROTEIN 2; N ACETYLGALACTOSAMINYLTRANSFERASE; NEL LIKE 2 PROTEIN; NLR FAMILY PYRIN DOMAIN CONTAINING 3 PROTEIN; PENTRAXIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE REGULATORY SUBUNIT 1; PROTEASE SERINE 23; PROTEIN; PROTEINASE; RECEPTOR INTERACTING PROTEIN 140; SEX COMB ON MIDLEG LIKE 1 PROTEIN; TBC1 DOMAIN FAMILY MEMBER 8 PROTEIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR MAFB; UDP N ACETYL ALPHA DEXTRO GALACTOSAMINE POLYPEPTIDE N ACETYLGALACTOSAMINYLTRANSFERASE 3; UNCLASSIFIED DRUG; WAS PROTEIN FAMILY MEMBER 2 PROTEIN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TCF7 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; GENE EXPRESSION; GENE EXPRESSION BASED RISK SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTIVE VALUE; RISK ASSESSMENT; SCORING SYSTEM; TIME TO TREATMENT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROARRAY ANALYSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; T CELL TRANSCRIPTION FACTOR 1; TREATMENT OUTCOME;

EID: 84901754270     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/423174     Document Type: Article

References (52)

1. Chiorazzi N., Rai K. R., Ferrarini M., Chronic lymphocytic leukemia. The New England Journal of Medicine 2005 352 8 804 815 2-s2.0-13844307760 10.1056/NEJMra041720 (Pubitemid 40271175)
2. Hallek M., Cheson B. D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M. J., Montserrat E., Rai K. R., Kipps T. J., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111 12 5446 5456 2-s2.0-45149100665 10.1182/blood-2007-06-093906
3. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., Belhoul L., Stella S., Stavroyianni N., Crespo M., Hadzidimitriou A., Sutton L., Bosch F., Laoutaris N., Anagnostopoulos A., Montserrat E., Fassas A., Dighiero G., Caligaris-Cappio F., Merle-Béral H., Ghia P., Davi F., Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007 109 1 259 270 2-s2.0-33846108722 10.1182/blood-2006-03-012948 (Pubitemid 46070124)
4. Rassenti L. Z., Huynh L., Toy T. L., Chen L., Keating M. J., Gribben J. G., Neuberg D. S., Flinn I. W., Rai K. R., Byrd J. C., Kay N. E., Greaves A., Weiss A., Kipps T. J., ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine 2004 351 9 893 901 2-s2.0-4143105617 10.1056/NEJMoa040857 (Pubitemid 39096916)
5. Rassenti L. Z., Jain S., Keating M. J., Wierda W. G., Grever M. R., Byrd J. C., Kay N. E., Brown J. R., Gribben J. G., Neuberg D. S., He F., Greaves A. W., Rai K. R., Kipps T. J., Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008 112 5 1923 1930 2-s2.0-52649143664 10.1182/blood-2007-05- 092882
6. Mead J. R., Irvine S. A., Ramji D. P., Lipoprotein lipase: structure, function, regulation, and role in disease. Journal of Molecular Medicine 2002 80 12 753 769 2-s2.0-0036460675 10.1007/s00109-002-0384-9 (Pubitemid 35478124)
7. Orchard J. A., Ibbotson R. E., Davis Z., Wiestner A., Rosenwald A., Thomas P. W., Hamblin T. J., Staudt L. M., Oscier D. G., ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. The Lancet 2004 363 9403 105 111 2-s2.0-0347318114 10.1016/S0140-6736(03)15260-9 (Pubitemid 38068326)
8. Josefsson P., Geisler C. H., Leffers H., Petersen J. H., Andersen M. K., Jurlander J., Buhl A. M., CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007 109 11 4973 4979 2-s2.0-34249651313 10.1182/blood-2006-11-054916 (Pubitemid 46827796)
9. Herling M., Patel K. A., Weit N., Lilienthal N., Hallek M., Keating M. J., Jones D., High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009 114 21 4675 4686 2-s2.0-73949158411 10.1182/blood-2009-03-208256
10. Stamatopoulos B., Meuleman N., Haibe-Kains B., Saussoy P., Van Den Neste E., Michaux L., Heimann P., Martiat P., Bron D., Lagneaux L., microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009 113 21 5237 5245 2-s2.0-67149147424 10.1182/blood-2008-11-189407
11. Zucchetto A., Bomben R., Dal Bo M., Sonego P., Nanni P., Rupolo M., Bulian P., Dal Maso L., Del Poeta G., Del Principe M. I., Degan M., Gattei V., A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. Journal of Cellular Physiology 2006 207 2 354 363 2-s2.0-33645676036 10.1002/jcp.20570
12. Rodríguez A., Villuendas R., Yáñez L., Gómez M. E., Díaz R., Pollán M., Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007 21 1984 1991 (Pubitemid 47299974)
13. Kienle D., Benner A., Läufle C., Winkler D., Schneider C., Bühler A., Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica 2010 95 102 109
14. Stamatopoulos B., Meuleman N., de Bruyn C., Pieters K., Anthoine G., Mineur P., Bron D., Lagneaux L., A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS ONE 2010 5 9 1 12 2-s2.0-77958541352 10.1371/journal.pone.0012780 e12780
15. Herold T., Jurinovic V., Metzeler K. H., Boulesteix A.-L., Bergmann M., Seiler T., Mulaw M., Thoene S., Dufour A., Pasalic Z., Schmidberger M., Schmidt M., Schneider S., Kakadia P. M., Feuring-Buske M., Braess J., Spiekermann K., Mansmann U., Hiddemann W., Buske C., Bohlander S. K., An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 2011 25 10 1639 1645 2-s2.0-80054040682 10.1038/leu.2011.125
16. Chuang H.-Y., Rassenti L., Salcedo M., Licon K., Kohlmann A., Haferlach T., Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 2012 120 2639 2649
17. Herold T., Jurinovic V., Mulaw M., Seiler T., Dufour A., Schneider S., Kakadia P. M., Feuring-Buske M., Braess J., Spiekermann K., Mansmann U., Hiddemann W., Buske C., Bohlander S. K., Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes Chromosomes and Cancer 2011 50 7 546 558 2-s2.0-79955661909 10.1002/gcc.20879
18. Kassambara A., Hose D., Moreaux J., Walker B. A., Rotopopov A., Reme T., Pellestor F., Pantesco V., Jauch A., Morgan G., Goldschmidt H., Klein B., Genes with a spike expression are clustered in chromosome (sub) bands and spike (sub) bands have a powerful prognostic value in patients with multiple Myeloma. Haematologica 2012 97 4 622 630 2-s2.0-84859476869 10.3324/haematol.2011.046821
19. Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005 102 43 15545 15550 2-s2.0-27344435774 10.1073/pnas.0506580102 (Pubitemid 41528093)
20. Bret C., Klein B., Moreaux J., Gene expression-based risk score in diffuse large B-cell lymphoma. Oncotarget 2013 3 1700 1710
21. Rosenquist R., Cortese D., Bhoi S., Mansouri L., Gunnarsson R., Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leukemia & Lymphoma 2013 54 2351 2364
22. van't Veer M. B., Brooijmans A. M., Langerak A. W., Verhaaf B., Goudswaard C. S., Graveland W. J., Van Lom K., Valk P. J. M., The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006 91 1 56 63 2-s2.0-32544451164 (Pubitemid 43235386)
23. Nautiyal J., Steel J. H., Mane M. R., Oduwole O., Poliandri A., Alexi X., The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals. Development 2013 140 1079 1089
24. Reya T., O'Riordan M., Okamura R., Devaney E., Willert K., Nusse R., Grosschedl R., Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000 13 1 15 24 2-s2.0-0033711624
25. Ranheim E. A., Kwan H. C. K., Reya T., Wang Y.-K., Weissman I. L., Francke U., Frizzled 9 knock-out mice have abnormal B-cell development. Blood 2005 105 6 2487 2494 2-s2.0-15244345063 10.1182/blood-2004-06-2334 (Pubitemid 40387050)
26. Roose J., Huls G., van Beest M., Moerer P., van der Horn K., Goldschmeding R., Logtenberg T., Clevers H., Synergy between tumor suppressor APC and the β -catenin-Tcf4 target Tcf1. Science 1999 285 5435 1923 1926 2-s2.0-0033578918 10.1126/science.285.5435.1923 (Pubitemid 29444623)
27. Huls G., van Es J., Clevers H., de Haan G., van Os R., Loss of Tcf7 diminishes hematopoietic stem/progenitor cell function. Leukemia 2013 7 1613 1614
28. Zenz T., Kröber A., Scherer K., Häbe S., Bühler A., Benner A., Denzel T., Winkler D., Edelmann J., Schwänen C., Döhner H., Stilgenbauer S., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008 112 8 3322 3329 2-s2.0-54049141334 10.1182/blood-2008-04-154070
29. Bou Samra E., Klein B., Commes T., Moreaux J., Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget 2012 3 824 832
30. Moreaux J., Klein B., Bataille R., Descamps G., Maïga S., Hose D., Goldschmidt H., Jauch A., Rème T., Jourdan M., Amiot M., Pellat-Deceunynck C., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011 96 4 574 582 2-s2.0-79953892192 10.3324/haematol.2010.033456
31. Sevov M., Rosenquist R., Mansouri L., RNA-based markers as prognostic factors in chronic lymphocytic leukemia. Expert Review of Hematology 2012 5 1 69 79 2-s2.0-84856248636 10.1586/ehm.11.80
32. Docquier A., Harmand P.-O., Fritsch S., Chanrion M., Darbon J.-M., Cavaillès V., The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clinical Cancer Research 2010 16 11 2959 2970 2-s2.0-77953102583 10.1158/1078-0432.CCR-09-3153
33. Docquier A., Augereau P., Lapierre M., Harmand P.-O., Badia E., Annicotte J.-S., The RIP140 gene is a transcriptional target of E2F1. PLoS ONE 2012 7 e35839
34. Baldus C. D., Liyanarachchi S., Mrózek K., Auer H., Tanner S. M., Guimond M., Ruppert A. S., Mohamed N., Davuluri R. V., Caligiuri M. A., Bloomfield C. D., De La Chapelle A., Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proceedings of the National Academy of Sciences of the United States of America 2004 101 11 3915 3920 2-s2.0-12144290701 10.1073/pnas.0400272101 (Pubitemid 38381077)
35. Haslinger C., Schweifer N., Stilgenbauer S., Döhner H., Lichter P., Kraut N., Stratowa C., Abseher R., Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. Journal of Clinical Oncology 2004 22 19 3937 3949 2-s2.0-5444276626 10.1200/JCO.2004.12.133 (Pubitemid 41079876)
36. Wu J. Q., Seay M., Schulz V. P., Hariharan M., Tuck D., Lian J., Du J., Shi M., Ye Z., Gerstein M., Snyder M. P., Weissman S., Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line. PLoS Genetics 2012 8 3 2-s2.0-84859222400 10.1371/journal.pgen.1002565 e1002565
37. Logan C. Y., Nusse R., The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology 2004 20 781 810 2-s2.0-8444251784 10.1146/annurev.cellbio.20.010403.113126 (Pubitemid 39488658)
38. Lu D., Zhao Y., Tawatao R., Cottam H. B., Sen M., Leoni L. M., Kipps T. J., Corr M., Carson D. A., Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 3118 3123 2-s2.0-1542267803 10.1073/pnas.0308648100 (Pubitemid 38327744)
39. Etet P. F. S., Vecchio L., Nwabo Kamdje A. H., Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cellular Signalling 2012 24 7 1433 1443 2-s2.0-84860001611 10.1016/j.cellsig.2012.03.008
40. Ge X., Wang X., Role of Wnt canonical pathway in hematological malignancies. Journal of Hematology & Oncology 2010 3 33
41. Abbott B. L., Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. The Oncologist 2006 11 1 21 30 2-s2.0-31444456641 10.1634/theoncologist.11-1-21 (Pubitemid 43152683)
42. Weeda G., Donker I., de Wit J., Morreau H., Janssens R., Vissers C. J., Nigg A., Van Steeg H., Bootsma D., Hoeijmakers J. H. J., Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Current Biology 1997 7 6 427 439 2-s2.0-12644266319 (Pubitemid 27274796)
43. Geleziunas R., McQuillan A., Malapetsa A., Hutchinson M., Kopriva D., Wainberg M. A., Hiscott J., Bramson J., Panasci L., Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustard. Journal of the National Cancer Institute 1991 83 8 557 564 2-s2.0-0025856732
44. Clingen P. H., de Silva I. U., McHugh P. J., Ghadessy F. J., Tilby M. J., Thurston D. E., Hartley J. A., The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Research 2005 33 10 3283 3291 2-s2.0-20844442267 10.1093/nar/gki639 (Pubitemid 41194472)
45. Pepper C., Lowe H., Fegan C., Thurieau C., Thurston D. E., Hartley J. A., Delavault P., Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. British Journal of Cancer 2007 97 2 253 259 2-s2.0-34447295687 10.1038/sj.bjc.6603853 (Pubitemid 47057474)
46. Barret J. M., Cadou M., Hill B. T., Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochemical Pharmacology 2002 63 2 251 258 2-s2.0-0037081754 10.1016/S0006-2952(01)00835-8 (Pubitemid 34158826)
47. King B. S., Cooper K. L., Liu K. J., Hudson L. G., Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair. The Journal of Biological Chemistry 2012 287 39824 39833
48. Michaux L., Wlodarska I., Rack K., Stul M., Criel A., Maerevoet M., Marichal S., Demuynck H., Mineur P., Samani K. K., Van Hoof A., Ferrant A., Marynen P., Hagemeijer A., Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. Leukemia 2005 19 1 77 82 2-s2.0-19944427177 10.1038/sj.leu.2403543 (Pubitemid 40090080)
49. Burger J. A., Burger M., Kipps T. J., Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999 94 11 3658 3667 2-s2.0-0033485625
50. Burger J. A., Tsukada N., Burger M., Zvaifler N. J., Dell'Aquila M., Kipps T. J., Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000 96 8 2655 2663 2-s2.0-0034667624
51. McCaig A. M., Cosimo E., Leach M. T., Michie A. M., Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS ONE 2012 7 e48929
52. Sivina M., Hartmann E., Kipps T. J., Rassenti L., Krupnik D., Lerner S., LaPushin R., Xiao L., Huang X., Werner L., Neuberg D., Kantarjian H., O'Brien S., Wierda W. G., Keating M. J., Rosenwald A., Burger J. A., CCL3 (MIP-1 α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011 117 5 1662 1669 2-s2.0-79551629508 10.1182/blood-2010-09-307249